Reference : Vertebral anti-fracture efficacy of strontium ranelate according to pre-treatment bone t...
Scientific journals : Article
Human health sciences : Rheumatology
Human health sciences : General & internal medicine
http://hdl.handle.net/2268/10177
Vertebral anti-fracture efficacy of strontium ranelate according to pre-treatment bone turnover.
English
Collette, Julien mailto [Centre Hospitalier Universitaire de Liège - CHU > > Chimie médicale >]
Bruyère, Olivier mailto [Université de Liège - ULg > Département des sciences de la santé publique > Epidémiologie et santé publique >]
Kaufman, J. M. [> > > >]
Lorenc, R. [> > > >]
Felsenberg, D. [> > > >]
Spector, T. D. [> > > >]
Diaz-Curiel, M. [> > > >]
Boonen, S. [> > > >]
Reginster, Jean-Yves mailto [Université de Liège - ULg > Département des sciences de la santé publique > Epidémiologie et santé publique >]
2010
Osteoporosis International
Springer Science & Business Media B.V.
21
2
233-41
Yes (verified by ORBi)
International
0937-941X
1433-2965
Godalming
United Kingdom
[en] Osteoporotic post-menopausal women patients in two randomised trials comparing the anti-fracture efficacy of strontium ranelate with placebo were separated into tertiles according to their baseline levels of biochemical markers of bone formation and resorption. The vertebral anti-fracture efficacy of strontium ranelate was shown to be independent of baseline bone turnover levels. INTRODUCTION: Bone turnover (BTO) levels vary among women at risk of osteoporotic fracture. Strontium ranelate is an anti-osteoporotic treatment increasing bone formation and reducing bone resorption. It was hypothesised that its anti-fracture efficacy would be independent of baseline BTO levels. METHODS: Post-menopausal women with osteoporosis from two pooled studies were stratified in tertiles according to baseline levels of two BTO markers: bone-specific alkaline phosphatase (b-ALP, n = 4995) and serum C-telopeptide cross-links (sCTX, n = 4891). Vertebral fracture risk was assessed over 3 years with strontium ranelate 2 g/day or placebo. RESULTS: In the placebo group, relative risk of vertebral fractures increased with BTO tertiles by 32% and 24% for patients in the highest tertile for b-ALP and CTX, respectively, compared to those in the lowest tertile. In the strontium ranelate group, incidences of vertebral fracture did not differ significantly across BTO tertiles. Significant reductions in vertebral fractures with strontium ranelate were seen in all tertiles of both markers, with relative risk reductions of 31% to 47% relative to placebo. Risk reduction did not differ among tertiles (b-ALP: p = 0.513; sCTX: p = 0.290). CONCLUSION: The vertebral anti-fracture efficacy of strontium ranelate was independent of baseline BTO levels. Strontium ranelate offers clinical benefits to women across a wide range of metabolic states.
http://hdl.handle.net/2268/10177
also: http://hdl.handle.net/2268/17923
10.1007/s00198-009-0940-z

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
Vertebral anti-fracture efficacy of strontium ranelate according to pre-treatment bone turnover.pdfPublisher postprint168.67 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.